MX2024000526A - Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os. - Google Patents

Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.

Info

Publication number
MX2024000526A
MX2024000526A MX2024000526A MX2024000526A MX2024000526A MX 2024000526 A MX2024000526 A MX 2024000526A MX 2024000526 A MX2024000526 A MX 2024000526A MX 2024000526 A MX2024000526 A MX 2024000526A MX 2024000526 A MX2024000526 A MX 2024000526A
Authority
MX
Mexico
Prior art keywords
children
natriuretic peptide
type natriuretic
skeletal dysplasia
peptide variants
Prior art date
Application number
MX2024000526A
Other languages
English (en)
Inventor
Jonathan Day
Elena Fisheleva
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2024000526A publication Critical patent/MX2024000526A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biochemistry (AREA)

Abstract

La presente descripción proporciona el uso de variantes del péptido natriurético tipo C (CNP), para el tratamiento de displasias esqueléticas en niños, y la mejora en uno o más síntomas de displasias esqueléticas, tales como el crecimiento de los huesos largos o la velocidad de crecimiento, y el uso en otros trastornos que tienen una displasia esquelética y/o un síntoma o componente asociado al CNP.
MX2024000526A 2021-07-09 2022-07-11 Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os. MX2024000526A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220275P 2021-07-09 2021-07-09
US202263350196P 2022-06-08 2022-06-08
PCT/US2022/073605 WO2023283657A1 (en) 2021-07-09 2022-07-11 C-type natriuretic peptide variants to treat skeletal dysplasia in children

Publications (1)

Publication Number Publication Date
MX2024000526A true MX2024000526A (es) 2024-02-02

Family

ID=83152005

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000526A MX2024000526A (es) 2021-07-09 2022-07-11 Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.

Country Status (12)

Country Link
US (1) US20230140311A1 (es)
EP (1) EP4366758A1 (es)
JP (1) JP2024525562A (es)
KR (1) KR20240035811A (es)
AU (1) AU2022306598A1 (es)
CA (1) CA3226388A1 (es)
CL (1) CL2024000069A1 (es)
CO (1) CO2024000658A2 (es)
IL (1) IL309798A (es)
MX (1) MX2024000526A (es)
TW (1) TW202313663A (es)
WO (1) WO2023283657A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE121102T1 (de) 1990-04-20 1995-04-15 Hisayuki Matsuo Neue im schwein vorkommende physiologisch aktive peptide.
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
WO1994020534A1 (en) 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
JP4825667B2 (ja) 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
CA2705603A1 (en) 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
ES2608457T3 (es) 2009-05-20 2017-04-11 Biomarin Pharmaceutical Inc. Variantes de péptido natriurético de tipo C
US9907834B2 (en) 2015-07-30 2018-03-06 Biomarin Pharmaceutical Inc. Use of C-type natriuretic peptide variants to treat skeletal dysplasia
BR112022002582A2 (pt) * 2019-08-12 2022-10-04 Biomarin Pharm Inc Sais de peptídeo hidrofóbicos para composições de liberação prolongada
EP4031183A1 (en) * 2019-09-16 2022-07-27 BioMarin Pharmaceutical Inc. Cnp variants and conjugates thereof

Also Published As

Publication number Publication date
JP2024525562A (ja) 2024-07-12
CL2024000069A1 (es) 2024-07-19
WO2023283657A1 (en) 2023-01-12
IL309798A (en) 2024-02-01
US20230140311A1 (en) 2023-05-04
CA3226388A1 (en) 2023-01-12
CO2024000658A2 (es) 2024-04-18
EP4366758A1 (en) 2024-05-15
TW202313663A (zh) 2023-04-01
KR20240035811A (ko) 2024-03-18
AU2022306598A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
MX2024000526A (es) Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.
MX2023002973A (es) Uso de variantes de peptido natriuretico de tipo c para tratar displasia esqueletica.
MX2022003184A (es) Variantes del cnp y sus conjugados.
MX2018006986A (es) Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.
MX2015008226A (es) Metodos para modular la homeostasis de los acidos biliares, y tratamiento de trastornos y enfermedades causadas por los acidos biliares.
DE69113029D1 (de) Verwendung von vitamin-d-analoga zur behandlung von akne.
CR20210342A (es) Derivados de oxopiridina sustituidos
CR20210545A (es) Formas sólidas de un inhibidor de glyt1
WO2020033867A3 (en) Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
MX2010001543A (es) Peptidos de surfactante pulmonar sintetico.
MX2021004387A (es) Composiciones y metodos para el tratamiento de sindrome vascular de ehlers danlos y trastornos asociados.
MX2021006488A (es) Composiciones para mejorar la funcion sexual.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
Kunac et al. Endoscopic treatment of the external snapping hip syndrome: surgical technique and report of two cases
MX2023009499A (es) Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica.
MX2022003010A (es) Tratamiento de la emr mediante cambio de terapia.
MX2022004236A (es) Maiz macerado soluble.
MX2020013869A (es) Lubricina para uso en curacion de heridas referencia cruzada con solicitudes relacionadas.
PH12020500606A1 (en) Use of functionalized calcium carbonate as active ingredient
CA3242257A1 (en) C-type natriuretic peptide therapy of bone-related disorders
UY37841A (es) Procedimiento de ataque ácido de una fuente de fosfato
MX2020014264A (es) Microdosis para antiestres e insomnio.
Vishnu et al. Functional Disability at 3 Months in Patients with Residual Limb Swelling after Snakebite Envenoming
MX2024002722A (es) Tratamiento de las alteraciones del sueño en pacientes del transtorno del espectro autista.
MX2023011283A (es) Uso de mebendazol para tratar infecciones virales.